2023
Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis
Bougie D, Reese S, Birch R, Bookwalter D, Mitchell P, Roh D, Kreuziger L, Cable R, Goel R, Gottschall J, Hauser R, Hendrickson J, Hod E, Josephson C, Kahn S, Kleinman S, Mast A, Ness P, Roubinian N, Sloan S, Study‐IV‐Pediatric F. Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion 2023, 63: 960-972. PMID: 36994786, PMCID: PMC10175171, DOI: 10.1111/trf.17319.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsHazard ratioPatient outcomesMulticenter retrospective analysisPlatelet transfusion requirementsGroup O recipientsRecipient's blood groupRisk of mortalitySpecific patient populationsBlood group ARecipient EpidemiologyTransfusion requirementsB recipientsOverall cohortProspective studyO recipientsPatient populationRetrospective analysisPlatelet dosesGroup ATransfusionABO antigensABO groupPatient exposureSignificant association
2022
Transfusion in infants and children
Hendrickson J, Josephson C. Transfusion in infants and children. 2022, 381-391. DOI: 10.1002/9781119719809.ch34.Peer-Reviewed Original ResearchRed blood cell transfusionGraft-versushost diseaseEtiology of anemiaBlood cell transfusionRisk of thrombosisSequestration of plateletsPotential adverse effectsActive bleedingCell transfusionPreterm infantsTransfusion supportCryoprecipitate transfusionOxygen-carrying capacityPediatric patientsPlatelet transfusionsTransfusionFactor VIIIThrombocytopeniaDecreased productionInfantsThawed plasmaAdverse effectsFactor XIIIAcellular productsChildren
2018
HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study
Nickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816. DOI: 10.1182/blood-2018-99-114116.Peer-Reviewed Original ResearchBone marrow transplantHLA class ISickle cell diseaseHLA-identical bone marrow transplantsMore platelet transfusionsNon-alloimmunized patientsPlatelet transfusion supportPlatelet transfusionsRBC transfusionClass IPositive PRAPre-BMTTransfusion supportPediatric patientsMarrow transplantCell diseaseBone marrowRed blood cell transfusionHepatic sinusoidal obstruction syndromeApheresis platelet transfusionHLA-disparate donorsBlood cell transfusionSinusoidal obstruction syndromePlatelet transfusion requirementsCord blood grafts
2017
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation
Hendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseRed blood cellsTransfusion supportTransplant physiciansConditioning regimen intensityOptimal transplant outcomesPeri-transplant periodHigher red blood cellStem cell transplantationTransfusion medicine physiciansRegimen intensityUndergoing transplantationPosttransplant periodTransplant outcomesHSCT populationCurative therapyPlatelet transfusionsSCD patientsTransfusion managementCell transplantationTransfusion therapyDonor selectionIron overloadCell disease
2015
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138. DOI: 10.1182/blood.v126.23.1138.1138.Peer-Reviewed Original ResearchRed blood cell transfusionNon-bleeding patientsBlood cell transfusionBone marrow biopsyBlood product transfusionSouthwest Oncology GroupPlatelet transfusionsOutpatient settingAcute leukemiaPlatelet levelsCell transfusionHemoglobin levelsTransfusion practiceLumbar punctureFibrinogen levelsProduct transfusionHospitalized patientsOncology GroupClinical trialsPlatelet thresholdMost respondersConsensus evidence-based guidelinesMost providersEastern Cooperative Oncology GroupStable hospitalized patients
2014
CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following Transfusion
Patel S, Arthur C, Rodrigues L, Xue C, Zimring J, Hendrickson J, Stowell S. CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following Transfusion. Blood 2014, 124: 596. DOI: 10.1182/blood.v124.21.596.596.Peer-Reviewed Original ResearchPlatelet-rich plasmaMajor histocompatibility complexNK cell depletionT cellsPlatelet clearanceC57BL/6 recipientsPlatelet transfusionsNK cellsCellular immunityCell depletionAnti-MHC antibodiesSubsequent blood transfusionDepletion of CD8Solid organ allograftsAnti-platelet antibodiesCD8 T cellsClearance of plateletsPlatelet transfusion therapyFlow cytometric analysisLater time pointsC57BL/6 donorsMHC alloantibodiesNK1.1 antibodyOrgan allograftsBlood transfusion
2010
MHC II on transfused murine blood is not required for alloimmunization against MHC I
Gilson C, Cadwell C, Smith N, Hendrickson J, Zimring J. MHC II on transfused murine blood is not required for alloimmunization against MHC I. Vox Sanguinis 2010, 99: 369-374. PMID: 20546207, PMCID: PMC2955847, DOI: 10.1111/j.1423-0410.2010.01351.x.Peer-Reviewed Original ResearchConceptsMHC IMHC-IIBALB/c recipientsMajor histocompatibility complex IMHC-II expressionSubsequent platelet transfusionsHumoral alloimmunizationC recipientsPlatelet transfusionsHumoral responseNull donorsIgG subclassesMHC-II genesMouse modelAlloimmunizationC57BL/6 backgroundMurine bloodIndirect immunofluorescencePlatelet productsBloodRefractory stateTransfusionRecipientsMolecular mechanismsC57BL/6
2009
Chapter 47 Transfusion of HIV-positive Patients
Hendrickson J, Roback J. Chapter 47 Transfusion of HIV-positive Patients. 2009, 275-278. DOI: 10.1016/b978-0-12-374432-6.00047-6.Peer-Reviewed Original ResearchHIV-positive patientsAcquired Immunodeficiency SyndromeHuman immunodeficiency virusMultiple hematologic abnormalitiesSevere symptomatic anemiaUnderlying HIV infectionTransfusion of RBCsPotential immunomodulatory roleTransfusion-transmitted virusesTreatment of anemiaHIV diseaseSymptomatic anemiaHIV infectionImmunodeficiency syndromePlatelet transfusionsSevere thrombocytopeniaImmunodeficiency virusImmunomodulatory roleHematologic abnormalitiesHematologic conditionsVitamin deficiencyIneffective hematopoiesisTransfusionPatientsAdvanced stageChapter 49 Platelet Transfusion Refractory Patients
Hendrickson J, Roback J. Chapter 49 Platelet Transfusion Refractory Patients. 2009, 283-286. DOI: 10.1016/b978-0-12-374432-6.00049-x.Peer-Reviewed Original ResearchPlatelet refractory patientsHost diseaseRefractory patientsPlatelet refractoryAntibody detectionHuman leukocyte antigen alloimmunizationPlatelet transfusion-refractory patientsNon-immune causesTransfusion-associated graftLow platelet countHLA antibody detectionImmune causesImmunosuppressive medicationsPlatelet crossmatchingPlatelet refractorinessHLA antigensPlasma exchangePlatelet transfusionsPlatelet countPotential therapyPatientsTransfusionMedicationsGraftPlateletsChapter 46 Transfusion of Patients Undergoing HPC and Solid-organ Transplantation
Hendrickson J, Roback J. Chapter 46 Transfusion of Patients Undergoing HPC and Solid-organ Transplantation. 2009, 269-274. DOI: 10.1016/b978-0-12-374432-6.00046-4.Peer-Reviewed Original ResearchRed blood cellsTransfusion requirementsPlatelet transfusionsBlood productsFebrile non-hemolytic transfusion reactionsNon-hemolytic transfusion reactionsHematopoietic progenitor cell transplantationNon-myeloablative transplantsPreparative conditioning regimenRisk of transfusionSolid organ transplantationType of transplantProgenitor cell transplantationCategory of patientsTransfusion of bloodBlood product selectionFuture platelet transfusionABO mismatchMyeloablative transplantsConditioning regimenTransplant recipientsHLA alloimmunizationTransfusion triggerPlatelet refractorinessCell transplantation